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Abstract
Purpose To determine the utility of estimated glucose disposal rate (eGDR) as a candidate biomarker for thrombotic bio-
markers in patients with type 1 diabetes (T1D).
Methods We reanalysed baseline pretreatment data in a subset of patients with T1D from two previous RCTs, consisting of 
a panel of thrombotic markers, including fibrinogen, tissue factor (TF) activity, and plasminogen-activator inhibitor (PAI)-
1, and TNFα, and clinical factors (age, T1D duration, HbA1c, insulin requirements, BMI, blood pressure, and eGDR). 
We employed univariate linear regression models to investigate associations between clinical parameters and eGDR with 
thrombotic biomarkers.
Results Thirty-two patients were included [mean ± SD age 31 ± 7 years, HbA1c of 58 ± 9 mmol/mol (7.5 ± 0.8%), eGDR 
7.73 ± 2.61]. eGDR negatively associated with fibrinogen (P < 0.001), PAI-1 concentrations (P = 0.005), and TF activity 
(P = 0.020), but not TNFα levels (P = 0.881). We identified 2 clusters of patients displaying significantly different characteris-
tics; 56% (n = 18) were categorised as ‘higher-risk’, eliciting significantly higher fibrinogen (+ 1514 ± 594 μg/mL; P < 0.001), 
TF activity (+ 59.23 ± 9.42 pmol/mL; P < 0.001), and PAI-1 (+ 8.48 ± 1.58 pmol/dL; P < 0.001), HbA1c concentrations 
(+ 14.20 ± 1.04 mmol/mol; P < 0.001), age (+ 7 ± 3 years; P < 0.001), duration of diabetes (15 ± 2 years; P < 0.001), BMI 
(+ 7.66 ± 2.61 kg/m2; P < 0.001), and lower mean eGDR (− 3.98 ± 1.07; P < 0.001).
Conclusions Compared to BMI and insulin requirements, classical surrogates of insulin resistance, eGDR is a suitable and 
superior thrombotic risk indicator in T1D.
Trial registration ISRCTN4081115; registered 27 June 2017.
Keywords eGDR · Type 1 diabetes · Thrombosis · Cluster analysis
Introduction
Insulin resistance in type 1 diabetes (T1D) is an estab-
lished risk factor for cardiovascular disease [1, 2], retin-
opathy [3], and premature mortality [4]. The pathological 
linkage between insulin resistance and increased vascular 
risk is largely in virtue of an enhanced prothrombotic milieu 
[5–8]. Under normal conditions, insulin inhibits platelet 
aggregation and thrombosis via tissue factor (TF) inhibi-
tion and enhanced fibrinolytic action due to modulation of 
 * L. L. O’Mahoney 
 llom1@leicester.ac.uk
1 Diabetes Research Centre, Leicester General Hospital, 
University of Leicester, Leicester, UK
2 Carnegie School of Sport, Leeds Beckett University, Leeds, 
UK
3 Endocrinology and Metabolism Unit, Faculty of Medicine, 
Prince of Songkla University, Songkhla, Thailand
4 University of Leeds, Leeds Institute for Cardiovascular 
and Metabolic Medicine, Leeds, UK
5 Human Nutrition Research Centre, Newcastle University, 
Newcastle, UK
6 Faculty of Medical Science, Newcastle University, 
Population Health Science Institute, Newcastle, UK
7 School of Food Science and Nutrition, University of Leeds, 
Leeds, UK
8 School of Food Science and Biotechnology, Zhejiang 
Gongshang University, Hangzhou, China
9 University of Sunderland, Institute of Health Sciences 
and Wellbeing, Sunderland, UK
 Journal of Endocrinological Investigation
1 3
plasminogen activator inhibitor-1 (PAI-1) [6]. In contrast, 
both T1D [9] and insulin resistance are associated with a 
procoagulant plasma profile [10], whereby increased PA1-1 
and fibrinogen and reduced tissue plasminogen activator 
promotes atherothrombosis [11]. As such, identifying and 
treating insulin resistance in people with T1D represents 
an important therapeutic goal in reducing thrombotic bio-
markers and preventing the development of overt vascular 
complications.
However, the gold-standard technique for identifying and 
quantifying insulin resistance—the euglycaemic hyperinsu-
linaemic clamp—is time-consuming and invasive, rendering 
it impractical for use in routine clinical settings. Further, 
the use of individual clinical parameters in isolation, such 
as body mass index (BMI) or insulin dose requirements are 
crude indicators of insulin resistance in T1D. An alterna-
tive, is the use of estimated glucose disposal rate (eGDR), a 
validated marker of insulin resistance [12–14] which uses a 
combination of clinical parameters including HbA1c, BMI, 
and the presence of hypertension [15]. Research investigat-
ing the utility of eGDR has shown this metric to be associ-
ated with nephropathy [16] peripheral vascular disease [17], 
coronary artery disease [18, 19], and mortality [19] with 
lower eGDR values conferring greater risk. In the present 
study, we reanalysed data in a subset of patients with T1D 
from two RCTs and sought to explore the utility of eGDR as 
a candidate biomarker specifically for thrombotic biomark-
ers. Further, we applied an unsupervised, data-driven cluster 
analysis, to establish a novel classification for thrombosis in 
our cohort, based on shared commonalities between routine 
clinical parameters and thrombotic biomarkers.
Methods
We used data from two previous RCTs (Clinical trial reg-
istration: clinicaltrials.gov NCT02595658; ISRCTN regis-
tration ISRCTN40811115). Both studies received ethical 
approval from local National Health Service Research Eth-
ics Committees (REC reference 14/NE/1183; REC reference 
17/NE/0244) and all participants gave written informed 
consent.
Detailed information regarding each study has been 
published previously [9, 20]. In the present analysis, we 
included participants meeting the following inclusion cri-
teria: classical presentation of T1D (including primary 
osmotic symptoms, weight loss, hyperglycaemia, ketosis, 
insulin initiation at diagnosis); aged 18–50 years; diagnosed 
with T1D for a minimum of 5-years on enrolment; treated 
on a stable (> 12-months) basal-bolus insulin regimen con-
sisting of rapid-acting insulin analogues lispro or aspart 
and basal insulin glargine delivered through multiple daily 
injections or continuous subcutaneous insulin infusion; and 
free of diabetes-related complications.
We used baseline pretreatment data across both RCTs. 
In both studies, testing procedures were conducted during 
a morning-time laboratory visit with patients adopting an 
overnight fast (> 10-h). Fasted, rested, venous blood sam-
ples were obtained and retrospectively analysed for, tumour 
necrosis factor alpha (TNFα; Human TNFα Quantikine 
ELISA; R and D Systems, Roche Diagnostics, UK), plasma 
fibrinogen (ab108842, Fibrinogen Human ELISA Kit; 
Abcam, Japan), tissue factor activity (TF; Human Tissue 
Factor activity ab108906; Abcam, UK) and plasminogen 
activator inhibitor-1 (PAI-1; Human PAI-1/serpin ELISA 
Kit DSE100; R and D systems, UK) using methods pre-
viously described [9]; the intra-assay coefficient of varia-
tion was < 10% for all biochemical analysis. In addition, we 
obtained the following physiological characteristics (age, 
duration of diabetes, HbA1c, insulin requirements, BMI, 
blood pressure, and eGDR). Blood pressure was assessed 
via an automated oscillometric device (Intellisense HEM-
907XL, Omron, Japan); participants were categorised as 
hypertensive if ≥ 140/90mmHG, pre-existing physicians’ 
diagnosis, or antihypertensive use [21]. eGDR was calcu-
lated using a composite of BMI, HbA1c and hypertensive 
status using the following formulae: eGDR = 19.02—[0.22 
X BMI (kg/m2)]—(3.26 X HTN)—(0.61 X HbA1c (%)], 
whereby HTN is hypertension (1 = yes, 0 = no). eGDR was 
used as a diagnostic criterion for insulin resistance with 
lower eGDR values conferring greater degrees of insulin 
resistance [15].
Statistical analysis
Data were analysed using SPSS Statistics version 25 (IBM 
SPSS Statistics 25, IBM Corporation, USA) and checked 
for normality using Shaprio–Wilk’s test with a cut-point 
0.05. Descriptive characteristics of the study population 
are presented as mean ± SD for continuous variables and 
as frequency (%) for categorical variables; 95% confidence 
intervals (CIs) and β coefficients are presented where rel-
evant. To assess the association between clinical parameters 
and eGDR, a Pearson correlation coefficient matrix was 
employed. Univariate linear regression models were used to 
investigate the associations between clinical parameters and 
thrombotic biomarkers. To categorise and group individuals 
based on shared clinical and biochemical characteristics, we 
utilised two-step clustering with complete data available for 
continuous variables. In this unsupervised approach, the first 
step estimates the optimal number of clusters on the basis 
of silhouette width and the second step is based on Bayes-
ian hierarchical clustering. In this application, the method 
partitions clinical characteristics based on their abundance/
magnitude in the individuals, and partitions individuals 
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based on the abundance/magnitude of their characteristics. 
The optimal number of clusters was determined to be 2. We 
use standardised Z scores of variables and log-likelihood 
as a distance measure and Schwarz’s Bayesian criterion for 
clustering. Only continuous variables were included as the 
k-means method does not accommodate binary categorical 
variables. Cluster labels were assigned by examining cluster 
variable means. Differences between dichotomised variables 
were assessed with independent t-tests. Statistical signifi-
cance was set at P < 0.05 for all analyses.
Results
Baseline characteristics of patients included in the pre-
sent analysis are shown in Table 1. In summary, the 32 
T1D males had a mean age of 31 ± 7  years, HbA1c of 
58 ± 9 mmol/mol [7.5 ± 0.8%], and a mean eGDR value of 
7.73 ± 2.61. Figure 1 shows individual patient clinical pro-
files ranked by eGDR. To determine whether, and identify 
which, clinical parameters may serve as candidate biomark-
ers for a thrombotic biomarker profile, we applied a Pear-
son correlation coefficient matrix across variables (Fig. 2). 
eGDR was negatively correlated with fibrinogen (r = − 0.69; 
P < 0.001), PAI-1 concentrations (r = − 0.67; P = 0.005), 
and TF activity (r = − 0.36; P = 0.020), but not TNFα levels 
(r = − 0.19; P = 0.881). HbA1c, BMI, age, diabetes duration, 
and insulin requirements were positively correlated with 
thrombotic biomarkers (Fig. 2). The relationship between 
thrombotic biomarkers and clinical characteristics was fur-
ther examined using univariate regression analysis (Table 2). 
eGDR, HbA1c, BMI, age, diabetes duration, and insulin 
requirements were significantly associated with fibrinogen, 
TF activity, and PAI-1 concentrations, with eGDR provid-
ing the strongest association across the range of thrombotic 
biomarkers (Table 2). Multivariate modelling to assess for 
the contribution of the relationship between significant asso-
ciations could not be performed due to the small numbers 
of this study.
To identify whether clinical profiles could be used to clas-
sify patients into novel diabetes subgroups, we used a two-
step clustering method with the complete data available for 
continuous clustering variables. Figure 3 shows the cluster 
characteristics for cluster 1 and 2. Cluster 2, including 44% 
(n = 14) of the patients, was characterised by increased levels 
of vascular inflammatory proteins: fibrinogen, TF activity, 
PAI-1, and their mediator TNFα, a higher HbA1c, older age, 
a greater duration of diabetes, and increased BMI, and lower 
eGDR. These data imply that patients with a lower eGDR, 
a proxy of insulin resistance, concomitantly express raised 
levels of thrombotic biomarkers associated with adverse 
vascular health. To explore this hypothesis, we stratified 
patients according to their cluster allocation and performed 
independent t-tests on individual clinical parameters and 
thrombotic biomarkers (Fig. 4). Clinical parameters and 
thrombotic biomarkers of patients stratified by cluster allo-
cation can found in Online Resource 1. Notably, cluster 2, 
was categorised as a ‘higher-thrombotic profile’ group, with 
individuals eliciting significantly higher mean fibrinogen 
(cluster 1: 1559 ± 689 vs. cluster 2: 3073 ± 1283 μg/mL; 
P < 0.001), TF activity (cluster 1: 83.01 ± 39.20 vs. cluster 2: 
142.24 ± 48.62 pmol/mL; P = 0.001), and PAI-1 (cluster 1: 
8.62 ± 5.53 vs. cluster 2: 17.10 ± 7.11 pmol/dL; P = 0.001), 
HbA1c concentrations (cluster 1: 51.76 ± 5.72 vs. cluster 
2: 65.96 ± 4.68 mmol/mol; P < 0.001). Further, cluster 2, 
elicited a significantly higher mean age (cluster 1: 28 ± 5 
vs. cluster 2: 35 ± 7 years; P = 0.002), greater mean dura-
tion of diabetes (cluster 1: 10 ± 5 vs. cluster 2: 25 ± 7 years; 
P < 0.001), a higher mean BMI (cluster 1: 22.68 ± 1.51 vs. 
cluster 2: 30.34 ± 4.12 kg/m2; P < 0.001), and a lower mean 
eGDR (cluster 1: 9.47 ± 1.16 vs. cluster 2: 5.49 ± 2.23; 
P < 0.001).
Conclusions
In the present study, we examined, for the first time, the 
association between eGDR, a validated surrogate marker 
of insulin resistance, and thrombotic biomarkers in patients 
with T1D. Our findings suggest eGDR to be a suitable indi-
cator of a prothrombotic profile, and superior to BMI and 
Table 1  Baseline characteristics of patients
Metric variables presented as mean ± SD [Range]; categorical data 
presented as frequency (%)
eGDR estimated glucose disposal rate, TF activity tissue factor activ-
ity, PAI-1 Plasminogen activator inhibitor-1, TNFα tumour necrosis 
factor alpha
Clinical parameters
Age (years) 31 ± 7 [21–50]
BMI (kg/m2) 26.03 ± 4.82 [20–38]
Egdr 7.73 ± 2.61 [2.12–10.72]
Hypertension (%) 31
HbA1c [mmol.moL (%)] 57.97 ± 8.85 (7.45 ± 0.81) 
43.17–72.64 (6.10–8.80)
Diabetes duration (years) 17 ± 9 [4–42]
Total daily insulin requirements (IU) 42 ± 2 [83–8]
Rapid-acting insulin requirements 
(IU)
9 ± 3 [4–16]
Insulin apart users (%) 63
Vascular and inflammatory parameters
 TNFα (pg/mL) 4.28 ± 1.05 [2.30–6.01]
 Fibrinogen (μg/mL) 2221 ± 1238 [300–5060]
 TF activity (pmol/mL) 108.93 ± 52.20 [11.26–219.52]
 PAI-1 (pmol/dL) 12.33 ± 7.50 [4.48–30.09]
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insulin requirements which are classical surrogates of insulin 
resistance.
Whereas, previous attempts to assess the relationship 
between eGDR and vascular health have focused on estab-
lished microvascular complications [22], to the best of our 
knowledge, this is the first study that has aimed to assess 
whether, and which, clinical characteristics may serve as 
candidate biomarkers specifically for a heightened throm-
botic profile in the absence of established microvascular 
complications. Consequently, our data lend support to the 
use of eGDR as a tool for identifying T1D patients with a 
procoagulant profile prior to the presentation of overt vas-
cular complications. Further, established risk factors for 
complications in T1D, namely HbA1c, age, and disease 
duration [23–25] were also found to be associated with an 
adverse thrombotic profile in this group of relatively young, 
and well-controlled T1D adults. In addition to these clas-
sical risk factors, we propose that eGDR may serve as a 
useful clinical tool for targeting individuals requiring closer 
monitoring for early atherothrombosis and potential inter-
vention for insulin resistance.
As our data imply that patients with a lower eGDR, 
older age, longer duration of diabetes, and higher insu-
lin requirements, concomitantly express a procoagulant 
profile, a logical extension of the present study was to 
establish whether it was possible to classify patients based 
on shared commonalities in clinical characteristics and 
thrombotic biomarkers. To this end, we applied an unsu-
pervised, data-driven cluster analysis to establish a novel 
classification for an elevated thrombotic profile in T1D. 
Importantly, we used variables reflective of key aspects 
of diabetes management that can be easily obtained and 
monitored in patients, and thus this clustering can imple-
mented in both existing diabetes cohorts and patients in 
diabetes clinics. Within the ‘higher-thrombotic profile’ 
cluster, circulating concentrations of fibrinogen, TF activ-
ity, and PAI-1 were on average ~ twofold higher than lev-
els exhibited by patients in the ‘lower-thrombotic profile’ 
Fig. 1  Individual patient 
clinical profiles (y axis) ranked 
by eGDR (normalised data). 
eGDR, estimated glucose 
disposal rate; TF activity, 
Tissue Factor activity; PAI-1, 
Plasminogen Activator Inhibi-
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cluster. This was accompanied by ~ twofold lower eGDR 
score in the ‘higher-thrombotic profile’ cluster [eGDR: 
cluster 1 (lower-thrombotic profile) ~ 5.5 vs. cluster 2 
(higher-thrombotic profile) ~ 9.5] which is characteristic of 
a ‘double diabetes’ phenotype [15]—a cohort at increased 
cardiovascular risk [14]. For example, in a large longitu-
dinal cohort study, Nyström and colleagues [14] recently 
demonstrated an eGDR of eight or less to be associated 
with an increased risk of cardiovascular disease or death 
in individuals with T1D compared to individuals with an 
eGDR greater than eight where survival rates were identi-
cal to a matched reference population.
It is well established that an enhanced thrombotic envi-
ronment contributes to poor clinical outcomes in patients 
with diabetes [26]. TF activity levels are increased in peo-
ple with diabetes, which upregulates production of throm-
bin accelerating the risk of clot formation [6]. Moreover, 
raised fibrinogen concentrations, reflective of chronic low-
grade inflammation contributes to the formation of denser 
clots, and increased PAI-1 levels impair the fibrinolytic 
process [6]. Previous in vitro and in vivo studies have 
shown that individuals with type 2 diabetes, but not nec-
essarily T1D exhibit increased PAI-1 levels suggesting 
that insulin resistance rather than just hyperglycaemia per 
se, promotes increased antifibrinolytic protein production 
[27]. This would suggest that targeting insulin resistance 
specifically, and not just glycaemia, may have an important 
effect on PAI-1 levels. PAI-1 levels in our patients were, 
on average comparable to previous reports in complica-
tion-free T1D individuals [28]. However, we observed 
a large range in PAI-1 levels between our patients, with 
some individuals exhibiting levels similar to patients with 
type 2 diabetes [29]. Taken collectively, our findings high-
light a large degree of heterogeneity in the presentation 
of thrombotic biomarkers between T1D patients, which 
highlights the complexities involved in the management 
of elevated thrombotic profiles in this patient group and 
questions the appropriateness of managing T1D uniformly.
From this initial exploratory study, we cannot at this 
stage claim that the clusters present different and distinct 
phenotypes of T1D, or that the clustering applied herein is 
the optimal classification of an elevated thrombotic profile 
across the spectrum of T1D. Future prospective studies 
with larger cohorts should focus attempts on addressing 
this aim to refine stratification through the inclusion of 
additional cluster variables, such as genotypes, or genetic 
risk scores, and, to establish whether patients can move 
between clusters in response to therapy or intervention, 
Fig. 2  Pearson correlation 
coefficient matrix illustrat-
ing the association between 
baseline patient characteristics 
and eGDR. Pearson correlation 
coefficients (r) are highlighted 
in white text. eGDR, estimated 
Glucose Disposal Rate; TF 
activity, Tissue Factor activity; 
PAI-1, Plasminogen Activator 
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and apply resampling methods to derive the significance 
of identified groups. Limitations of this work include not 
screening for C-peptide or autoantibodies and therefore we 
cannot rule out the possibility of a T1D misdiagnosis [i.e. 
maturity on the basis of classical presentation (including 
primary osmotic symptoms, weight loss, hyperglycaemia, 
ketosis, insulin initiation at diagnosis)], and our relatively 
limited sample consisting of relatively young well-con-
trolled patients.
In conclusion, our findings suggest eGDR to be a suit-






















































































































































































































Fig. 3  Cluster characteristics. Variables are presented as standardised Z scores. eGDR, estimated Glucose Disposal Rate; TF activity, Tissue 
Factor activity; PAI-1, Plasminogen Activator Inhibitor-1; TNFα, Tumour Necrosis Factor alpha
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patients with a procoagulant profile prior to the presenta-
tion of overt vascular complications.
Supplementary Information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s40618- 021- 01550-3.
Acknowledgements The authors wish to thank the study participants 
for their time.
Author contribution LLO and MDC designed the research. LLO con-
ducted the research. RAA aided with recruitment. MDC, MH, and 
SP performed the statistical analysis. LLO, NP, SP, DJW, MH, RAA, 
and MDC wrote the paper. All authors read and approved the final 
manuscript.
Funding This research received no specific grant from any funding 
agency in the public, commercial, or not-for-profit sectors.
Data availability The data that support the findings of this study are 
available on request from the corresponding author.
Declarations 
Conflict of interest No conflicts of interest or competing interests rel-
evant to this article are reported.
Ethical approval The RCT received ethical approval from the UK 
National Health Service Health Research Authority (REC Reference 
17/NE/0244).
Informed consent All participants gave written informed consent.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.
References
 1. Donga E, Dekkers OM, Corssmit E, Romijn JA (2015) Insulin 
resistance in patients with type 1 diabetes assessed by glucose 
clamp studies: systematic review and meta-analysis. Eur J Endo-
crinol 173(1):101–109
 2. Schauer IE, Snell-Bergeon JK, Bergman BC, Maahs DM, Kre-
towski A, Eckel RH, Rewers M (2011) Insulin resistance, defec-
tive insulin-mediated fatty acid suppression, and coronary artery 
calcification in subjects with and without type 1 diabetes: the 
CACTI study. Diabetes 60(1):306–314
 3. Chaturvedi N, Sjoelie A-K, Porta M, Aldington SJ, Fuller JH, 
Songini M, Kohner EM (2001) Markers of insulin resistance are 
strong risk factors for retinopathy incidence in type 1 diabetes: 
the EURODIAB prospective complications study. Diabetes Care 
24(2):284–289
 4. Mäkinen V-P, Forsblom C, Thorn LM, Wadén J, Gordin D, 
Heikkilä O, Hietala K, Kyllönen L, Kytö J, Rosengård-Bärlund 
M (2008) Metabolic phenotypes, vascular complications, and 
premature deaths in a population of 4,197 patients with type 1 
diabetes. Diabetes 57(9):2480–2487
 5. Members ATF, Rydén L, Grant PJ, Anker SD, Berne C, Cosentino 
F, Danchin N, Deaton C, Escaned J, Hammes H-P (2013) ESC 
guidelines on diabetes, pre-diabetes, and cardiovascular diseases 
developed in collaboration with the EASD: the task force on dia-
betes, pre-diabetes, and cardiovascular diseases of the European 
Society of Cardiology (ESC) and developed in collaboration with 
the European Association for the Study of Diabetes (EASD). Eur 
Heart J 34(39):3035–3087
 6. Kearney K, Tomlinson D, Smith K, Ajjan R (2017) Hypofibrinoly-
sis in diabetes: a therapeutic target for the reduction of cardiovas-
cular risk. Cardiovasc Diabetol 16(1):34
 7. Grant P (2007) Diabetes mellitus as a prothrombotic condition. J 
Intern Med 262(2):157–172
 8. Vazzana N, Ranalli P, Cuccurullo C (2012) DavıG mellitus and 
thrombosis. Thromb Res 129:371–377
 9. Campbell MD, Walker M, Ajjan RA, Birch KM, Gonzalez JT, 
West DJ (2017) An additional bolus of rapid-acting insulin to 
normalise postprandial cardiovascular risk factors following a 
high-carbohydrate high-fat meal in patients with type 1 diabetes: 
a randomised controlled trial. Diab Vasc Dis Res 14(4):336–344
 10. Ozkul A, Turgut ET, Akyol A, Yenisey C, Kadikoylu G, Tataroglu 
C, Kiylioglu N (2010) The relationship between insulin resist-
ance and hypercoagulability in acute ischemic stroke. Eur Neurol 
64(4):201–206
 11. Paneni F, Beckman JA, Creager MA, Cosentino F (2013) Diabetes 
and vascular disease: pathophysiology, clinical consequences, and 
medical therapy: part I. Eur Heart J 34(31):2436–2443
 12. Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ (2000) 
Can clinical factors estimate insulin resistance in type 1 diabetes? 
Diabetes 49(4):626–632. https:// doi. org/ 10. 2337/ diabe tes. 49.4. 
626
 13. Epstein EJ, Osman JL, Cohen HW, Rajpathak SN, Lewis O, Cran-
dall JP (2013) Use of the estimated glucose disposal rate as a 
measure of insulin resistance in an urban multiethnic population 
with type 1 diabetes. Diabetes Care 36(8):2280–2285. https:// doi. 
org/ 10. 2337/ dc12- 1693
 14. Nyström T, Holzmann MJ, Eliasson B, Svensson AM, Sartipy U 
(2018) Estimated glucose disposal rate predicts mortality in adults 
with type 1 diabetes. Diabetes Obes Metab 20(3):556–563
 15. Kietsiriroje N, Pearson S, Campbell M, Ariëns RA, Ajjan RA 
(2019) Double diabetes: a distinct high-risk group? Diabetes Obes 
Metab 21(12):2609–2618
 16. Orchard TJ, Chang Y-F, Ferrell RE, Petro N, Ellis DE (2002) 
Nephropathy in type 1 diabetes: a manifestation of insulin resist-
ance and multiple genetic susceptibilities? Further evidence from 
the Pittsburgh Epidemiology of Diabetes Complication Study. 
Kidney Int 62(3):963–970
 17. Olson JC, Erbey JR, Forrest KY, Williams K, Becker DJ, Orchard 
TJ (2002) Glycemia (or, in women, estimated glucose disposal 
rate) predict lower extremity arterial disease events in type 1 dia-
betes. Metabol Clin Exp 51(2):248–254
Fig. 4  Patient characteristics stratified by cluster allocation. White 
circles = cluster 1; black circles = cluster 2. Statistically significant 
differences between clusters calculated using independent t-tests. * 
denotes P < 0.05; ** denotes P < 0.01; *** denotes P < 0.001. eGDR 
estimated glucose disposal rate, TF activity tissue factor activity, PAI-
1 plasminogen activator inhibitor-1, TNFα tumour necrosis factor 
alpha
◂
 Journal of Endocrinological Investigation
1 3
 18. Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KY-Z, 
Kinder LS, Ellis D, Becker DJ (2003) Insulin resistance–related 
factors, but not glycemia, predict coronary artery disease in 
type 1 diabetes: 10-year follow-up data from the Pittsburgh 
Epidemiology of Diabetes Complications study. Diabetes Care 
26(5):1374–1379
 19. Pambianco G, Costacou T, Orchard TJ (2007) The prediction of 
major outcomes of type 1 diabetes: a 12-year prospective evalua-
tion of three separate definitions of the metabolic syndrome and 
their components and estimated glucose disposal rate: the Pitts-
burgh Epidemiology of Diabetes Complications Study experience. 
Diabetes Care 30(5):1248–1254
 20. O’Mahoney LL, Dunseath G, Churm R, Holmes M, Boesch C, 
Stavropoulos-Kalinoglou A, Ajjan RA, Birch KM, Orsi NM, 
Mappa G, Price OJ, Campbell MD (2020) Omega-3 polyun-
saturated fatty acid supplementation versus placebo on vascular 
health, glycaemic control, and metabolic parameters in people 
with type 1 diabetes: a randomised controlled preliminary trial. 
Cardiovasc Diabetol 19(1):127–127. https:// doi. org/ 10. 1186/ 
s12933- 020- 01094-5
 21. NICE (2019) Hypertension in adults: diagnosis and management
 22. NICE guideline [NG136]. https:// www. nice. org. uk/ guida nce/ 
ng136. Accessed 12/05/2020
 23. Girgis CM, Scalley BD, Park KE (2012) Utility of the estimated 
glucose disposal rate as a marker of microvascular complications 
in young adults with type 1 diabetes. Diabetes Res Clin Pract 
96(3):e70–e72
 24. Nazaimoon WW, Letchuman R, Noraini N, Ropilah A, Zainal 
M, Ismail I, Mohamad WW, Faridah I, Singaraveloo M, Sheriff 
I (1999) Systolic hypertension and duration of diabetes mellitus 
are important determinants of retinopathy and microalbuminuria 
in young diabetics. Diabetes Res Clin Pract 46(3):213–221
 25. Rodrigues T, Canani L, Schvartzman P, Gross J (2011) Hyperten-
sion is the metabolic syndrome component most strongly associ-
ated with microvascular complications and coronary artery calci-
fication in type 1 diabetes. J Endocrinol Invest 34(3):e58–e63
 26. Nørgaard K, Feldt-Rasmussen B, Deckert T (1991) Is hyperten-
sion a major independent risk factor for retinopathy in type 1 
diabetes? Diabet Med 8(4):334–337
 27. Sumaya W, Wallentin L, James SK, Siegbahn A, Gabrysch K, 
Bertilsson M, Himmelmann A, Ajjan RA (2018) Fibrin clot 
properties independently predict adverse clinical outcome fol-
lowing acute coronary syndrome: a PLATO substudy. Eur Heart 
J 39(13):1078–1085
 28. King R, Ajjan R (2016) Hypoglycaemia, thrombosis and vascular 
events in diabetes. Taylor and Francis
 29. Adly AAM, Elbarbary NS, Ismail EAR, Hassan SR (2014) Plas-
minogen activator inhibitor-1 (PAI-1) in children and adoles-
cents with type 1 diabetes mellitus: relation to diabetic micro-
vascular complications and carotid intima media thickness. JDC 
28(3):340–347
 30. Yarmolinsky J, Barbieri NB, Weinmann T, Ziegelmann PK, Dun-
can BB, Schmidt MI (2016) Plasminogen activator inhibitor-1 
and type 2 diabetes: a systematic review and meta-analysis of 
observational studies. Sci Rep 6:17714
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
